How much revenue does Alphamab Oncology make?

Alphamab Oncology reported 566.24 million CNY in revenue for fiscal year 2025, down 11.5% from 640.08 million CNY in fiscal year 2024.

What companies are similar to Alphamab Oncology?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Keymed Biosciences Inc. (2162.HK), HBM Holdings Limited (2142.HK), CStone Pharmaceuticals (2616.HK), Lepu Biopharma Co., Ltd. (2157.HK).

Alphamab Oncology (9966.HK) Stock

About Alphamab Oncology

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the...

At a glance

Alphamab Oncology reported revenue of 566.24 million CNY for fiscal year 2025, down 11.5% from fiscal year 2024, and net income of -113.94 million CNY.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.